Skip to Content
MDPIMDPI

Advanced

CIMBCurrent Issues in Molecular Biology
PDF
  • Editorial
  • Open Access

18 December 2025

Physiology Reimagined: Molecular, Metabolic, and Microenvironmental Forces Driving Epithelial Cancers

and
1
Department of Physiology, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
2
Department of Radiology and Medical Imaging, “Foisor” Clinical Hospital of Orthopaedics, Traumatology and Osteoarticular TB, 021382 Bucharest, Romania
3
Department of Oral and Maxillofacial Surgery, “Carol Davila” Central Military Emergency Hospital, 010825 Bucharest, Romania
4
Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Titu Maiorescu University, 031593 Bucharest, Romania
Curr. Issues Mol. Biol.2025, 47(12), 1064;https://doi.org/10.3390/cimb47121064
This article belongs to the Special Issue Epithelial Cancers: From Molecular Mechanisms to Therapeutic Innovations
Version Notes
Order Reprints
Epithelial cancers represent a broad spectrum of tumors that develop from epithelia of the skin and glands, as well as the digestive, respiratory, urogenital, and gynecological tracts. Recent statistics show that in 2022, almost 20 million cancer cases and 9.7 million deaths resulting from cancer were reported. Several types of cancer continue to be diagnosed late, including ovarian cancer, with over 324,000 new cases and more than 200,000 deaths annually [1]. The heterogeneity of these tumors, driven by genetic mutations, epigenetic changes, and microenvironmental influences, complicates prognoses and responses to therapy [2]. Epithelial carcinogenesis is initiated and sustained by a multitude of genetic and epigenetic deregulations [3,4]. To explain this, a review of epithelial plasticity was conducted, and it highlighted that epigenetic changes (DNA methylation and histone modifications) contribute to tumor heterogeneity and the emergence of epithelial–mesenchymal hybrid states [2,3]. Epithelial–mesenchymal transition (EMT), a reversible process controlled by TGF-β, Snail, and TWIST, transforms epithelial cells into migratory and invasive cells, which could be reversed by mesenchymo-epithelial transition (MET) [2,5]; epithelial plasticity showed that epigenetic heterogeneity leads to the emergence of epithelial–mesenchymal hybrid states, associated with poor prognosis and resistance to treatments [6].
Metabolic dysfunctions are another essential feature of malignancy [7]. Studies on transmembrane amino acid transporters have revealed that breast cancer subtypes have distinct metabolic profiles: luminal forms can perform gluconeogenesis, the HER2+ subtype exhibits active fatty acid synthesis, and triple-negative cancers depend on glycolysis and pH-sensitive SLC transporters [8,9,10,11]. Oncogenic factors such as c-Myc, HIF-1α, and PI3K/Akt/mTOR regulate these pathways, and variations in intracellular pH determine the adaptation of amino acid flux [12,13]. Moreover, angiogenesis plays a crucial role in tumor progression [14]. Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) is the main mediator of VEGF signaling, and its activation induces dimerization; autophosphorylation and activation of the PI3K/Akt and MAPK pathways, stimulating endothelial cell proliferation; and migration [15,16,17]. These examples illustrate how small molecular changes can irreversibly affect the systems they are part of, considerably impacting the physiology of the entire organism.
The tumor microenvironment also involves vascular–immune interactions. In a neonatal cerebral ischemia model, the poly(ADP-ribose) polymerase inhibitor PJ34 prevented a decrease in blood flow in the internal carotid artery, and reduced both blood–brain barrier permeability and astrocytic death [18]. Although this study focuses on neuropathology, the results emphasize that DNA repair and maintenance of vascular integrity are also essential in tumorigenesis [18,19,20]. This result highlights the importance of DNA repair and vascular integrity in preventing oncogenic processes. Immune regulation is closely linked to tumor plasticity [21], and a recent study demonstrated that the cytokines IL-6, IL-10, and TGF-β secreted by immune cells can promote EMT in ovarian cancer, facilitating invasion and metastasis [22,23]. Therefore, modulating the immune response and blocking EMT could provide personalized therapies. Currently, extensive molecular studies across different cancer categories have led to the selection of patients and their categorization into distinct treatment pathways, thereby increasing the likelihood of reducing the prevalence of some cancers, such as ovarian cancer [1,24].
Medicinal plants can also influence oncogenic pathways. Withania somnifera (Ashwagandha) contains withaferin A, which induces apoptosis, generates oxidative stress, inhibits NF-κB and STAT3, blocks the cell cycle in the G2–M phase, and partially reverses EMT by inhibiting uPA and modulating Notch receptors [25]. Its popularity stems from the fact that it is less toxic than chemotherapy, but its clinical use requires rigorous studies [25,26]. This again reflects how understanding the molecular mechanisms of aggressive cancers can lead to treatment strategies as simple as administering natural substances. Early diagnosis of epithelial tumors remains a challenge [27]. They are characterized by a high mortality rate due to their late detection, as initial symptoms are nonspecific and existing biomarkers have low predictive value [28,29]. For neuroendocrine tumors, imaging of somatostatin receptors has evolved significantly. Our broad understanding of the five receptor types, thanks to the development of PET imaging, has led to agonist- and antagonist-related studies on how tumors form and how different diseases, like acromegaly or hyperinsulinism, function [30,31,32]. In addition, one review details the affinities of the different agonists (octreotide, lanreotide, pasireotide) and emphasizes that new antagonists could have therapeutic utility [32]. A key conclusion of this study is the clear superiority of PET radiotracers over SPECT agents for detecting neuroendocrine tumors. This work further emphasizes the need to integrate state-of-the-art PET technologies in the diagnosis and management of patients with neuroendocrine tumors [32]. It also highlights the variability in SSTR receptors across tumors and the utility of agonists and antagonists in a therapeutic context [33].
Technological advances are providing new modalities for detecting tumors. In the context of analyzing the cell membrane using microscopy, atomic combination is performed using an automated appraisal algorithm to assess the tumor cell’s capacity to reach a normal level [34]. Combination of atomic force microscopy with automated algorithms can differentiate epithelial cells from tumor cells and normal cells with a precision of 91%. In anatomical pathology, the GlandNet neural classifier achieves approximately 94% precision and 95% sensitivity on prostatic epithelial nuclei. This algorithm allows for the standardization of biopsy evaluation [34,35]. In vitro, three-dimensional immune organs derived from stem cells and primary tissues develop a fibrous structure that requires ex vivo testing and diversification for cancer mechanisms. However, these models enable standardization, vascularization, and integration with the multiorgan system [36]. Other accessible technologies enable the creation of 3D models or test models of various anticancer drugs, ranging from large-scale to patient-specific, eliminating invasive in vivo testing and creating reproducible models [37,38].
The authors of these multidisciplinary studies have underlined the importance of epithelial tumors and tumor control systems. Their findings, including molecular mechanisms ranging from EMT, metabolic regulation, and angiogenesis to modulation of immunity, provide a map of therapeutic targets that can be exploited for cancer treatment [39,40,41]. The implementation of biomarkers, non-invasive technologies (e.g., PET imaging, artificial intelligence), and organoid immunity enables personalized diagnostics and recurrence monitoring [36,42]. In addition, targeted therapies and the combined use of natural compounds or regenerative technologies (e.g., 3D bioprinting) pave the way for effective, less toxic therapies [43,44]. However, challenges related to therapeutic stress, cumulative toxicity, and treatment costs remain; therefore, to improve treatment for epithelial cancers on a global scale, continuous collaboration among physicians, clinicians, bioengineers, and data scientists is essential, with a focus on preventive and personalized medicine.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hong, M.-K.; Ding, D.-C. Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions. Diagnostics 2025, 15, 406. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Sacco, J.L.; Gomez, E.W. Epithelial–Mesenchymal Plasticity and Epigenetic Heterogeneity in Cancer. Cancers 2024, 16, 3289. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Ghafoor, S.; Garcia, E.; Jay, D.J.; Persad, S. Molecular Mechanisms Regulating Epithelial Mesenchymal Transition (EMT) to Promote Cancer Progression. Int. J. Mol. Sci. 2025, 26, 4364. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Triantaphyllopoulos, K.A.; Ragia, N.D.; Panagiotopoulou, M.-C.E.; Sourlingas, T.G. Integrating Inflammatory and Epigenetic Signatures in IBD-Associated Colorectal Carcinogenesis: Models, Mechanisms, and Clinical Implications. Int. J. Mol. Sci. 2025, 26, 9498. [Google Scholar] [CrossRef] [Scilit]
  5. Zhao, X.; Han, Z.; Liu, R.; Li, Z.; Mei, L.; Jin, Y. FBXO11 Mediates Ubiquitination of ZEB1 and Modulates Epithelial-to-Mesenchymal Transition in Lung Cancer Cells. Cancers 2024, 16, 3269. [Google Scholar] [CrossRef] [Scilit]
  6. Tataranu, L.G.; Turliuc, S.; Kamel, A.; Rizea, R.E.; Dricu, A.; Staicu, G.-A.; Baloi, S.C.; Rodriguez, S.M.B.; Manole, A.I.M. Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance. Curr. Issues Mol. Biol. 2024, 46, 9881–9894. [Google Scholar] [CrossRef] [Scilit]
  7. Paunovic, M.; Stojanovic, A.; Pokimica, B.; Martacic, J.D.; Cvetkovic, Z.; Ivanovic, N.; Vucic, V. Metabolic Reprogramming of Phospholipid Fatty Acids as a Signature of Lung Cancer Type. Cancers 2024, 16, 3320. [Google Scholar] [CrossRef] [Scilit]
  8. Ignatov, A.; Lempfer, S.; Mészáros, J.; Eggemann, H. Prognostic Impact of HER2 Low Status in Male Breast Cancer: Prospective Cohort Analysis. Cancers 2024, 16, 3399. [Google Scholar] [CrossRef] [Scilit]
  9. Hughes, D.C.; Gorzelitz, J.; Ortiz, A.; Cohen, L.; Parma, D.L.; Boggess, T.; Darby, N.T.; Balaji, S.; Ramirez, A.G. Impact of Six Months of Three Different Modalities of Exercise on Stress in Post-Treatment Breast Cancer Survivors. Cancers 2024, 16, 3398. [Google Scholar] [CrossRef] [Scilit]
  10. Sriramulu, S.; Thoidingjam, S.; Speers, C.; Nyati, S. Present and Future of Immunotherapy for Triple-Negative Breast Cancer. Cancers 2024, 16, 3250. [Google Scholar] [CrossRef] [Scilit]
  11. Dyachenko, E.I.; Bel’skaya, L.V. Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype. Curr. Issues Mol. Biol. 2025, 47, 4. [Google Scholar] [CrossRef] [Scilit]
  12. Begagić, E.; Bečulić, H.; Džidić-Krivić, A.; Kadić Vukas, S.; Hadžić, S.; Mekić-Abazović, A.; Šegalo, S.; Papić, E.; Muchai Echengi, E.; Pugonja, R.; et al. Understanding the Significance of Hypoxia-Inducible Factors (HIFs) in Glioblastoma: A Systematic Review. Cancers 2024, 16, 2089. [Google Scholar] [CrossRef] [Scilit]
  13. Bangash, A.A.; Alvi, S.S.; Bangash, M.A.; Ahsan, H.; Khan, S.; Shareef, R.; Villanueva, G.; Bansal, D.; Ahmad, M.; Kim, D.J.; et al. Honey Targets Ribosome Biogenesis Components to Suppress the Growth of Human Pancreatic Cancer Cells. Cancers 2024, 16, 3431. [Google Scholar] [CrossRef] [Scilit]
  14. Hernandez Vargas, S.; Aghaamiri, S.; Adams, J.T.; Bateman, T.M.; Acidi, B.; Ghosh, S.C.; Khalaj, V.; Kaseb, A.O.; Tran Cao, H.S.; Momeny, M.; et al. Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma: Implications for Cancer Biology and Therapeutic Applications. Curr. Oncol. 2025, 32, 512. [Google Scholar] [CrossRef] [Scilit]
  15. Lungu, C.N.; Mangalagiu, I.I.; Romila, A.; Nechita, A.; Putz, M.V.; Mehedinti, M.C. Molecular Mediated Angiogenesis and Vasculogenesis Networks. Int. J. Mol. Sci. 2025, 26, 6316. [Google Scholar] [CrossRef] [Scilit]
  16. Wang, S.; Li, Y.; Rong, M.; Li, Y.; Lu, Y.; Li, S.; Lee, D.; Xu, J.; Guo, Y. Ajuforrestin A Inhibits Tumor Proliferation and Migration by Targeting the STAT3/FAK Signaling Pathways and VEGFR-2. Biology 2025, 14, 908. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Ewell, S.M.; Burton, H.; Mochona, B. In Silico Screening of 1,3,4-Thiadiazole Derivatives as Inhibitors of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2). Curr. Issues Mol. Biol. 2024, 46, 11220–11235. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Bonnin, P.; Vitalis, T.; Schwendimann, L.; Boutigny, A.; Mohamedi, N.; Besson, V.C.; Charriaut-Marlangue, C. Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Reduces Brain Damage after Stroke in the Neonatal Mouse Brain. Curr. Issues Mol. Biol. 2021, 43, 301–312. [Google Scholar] [CrossRef] [Scilit]
  19. Hou, Y.; Ning, W.; Huhe, M.; Shu, C. Genome-Wide Detection of Leukemia Biomarkers from lincRNA–Protein-Coding Gene Interaction Networks in the Three-Dimensional Chromatin Structure. Curr. Issues Mol. Biol. 2025, 47, 384. [Google Scholar] [CrossRef] [Scilit]
  20. Caruntu, A.; Moraru, L.; Surcel, M.; Munteanu, A.; Costache, D.O.; Tanase, C.; Constantin, C.; Scheau, C.; Neagu, M.; Caruntu, C. Persistent Changes of Peripheral Blood Lymphocyte Subsets in Patients with Oral Squamous Cell Carcinoma. Healthcare 2022, 10, 342. [Google Scholar] [CrossRef] [Scilit]
  21. von Fournier, A.; Würflein, E.; Moratin, H.; Stöth, M.; Ehret Kasemo, T.; Herrmann, M.; Goncalves, M.; Hagen, R.; Hackenberg, S.; Gehrke, T.; et al. Cisplatin-Mediated IL-6 and IDO1 Suppression in Mesenchymal Stromal Cells: Implications for Tumor Microenvironment Modulation In Vitro. Curr. Issues Mol. Biol. 2025, 47, 231. [Google Scholar] [CrossRef] [Scilit]
  22. Kos, M.; Mertowska, P.; Mertowski, S.; Roliński, J.; Krasińska-Płachta, A.; Urbanowicz, T.; Gogacz, M.; Grywalska, E. From Defense to Disease: How the Immune System Fuels Epithelial–Mesenchymal Transition in Ovarian Cancer. Int. J. Mol. Sci. 2025, 26, 4041. [Google Scholar] [CrossRef] [Scilit]
  23. Żulicka, M.; Piątkowska, D.; Grzanka, D.; Bonowicz, K.; Jerka, D.; Gagat, M.; Antosik, P. The Prognostic Role of IL-6 and RBP4 in Colorectal Cancer. Biomedicines 2025, 13, 2257. [Google Scholar] [CrossRef] [Scilit]
  24. Pariza, G.; Mavrodin, C.; Potorac, A.; Munteanu, O.; Cîrstoiu, M.M. A Narrative Review of Clinical and Molecular Criteria for the Selection of Poor Candidates for Optimal Cytoreduction in Epithelial Ovarian Cancer. Life 2025, 15, 1318. [Google Scholar] [CrossRef] [Scilit]
  25. Kołodziejska, R.; Tafelska-Kaczmarek, A.; Pawluk, M.; Sergot, K.; Pisarska, L.; Woźniak, A.; Pawluk, H. Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer. Curr. Issues Mol. Biol. 2024, 46, 7668–7685. [Google Scholar] [CrossRef] [Scilit]
  26. Wadhwa, R.; Wang, J.; Shefrin, S.; Zhang, H.; Sundar, D.; Kaul, S.C. Molecular Insights into the Anticancer Activity of Withaferin-A: The Inhibition of Survivin Signaling. Cancers 2024, 16, 3090. [Google Scholar] [CrossRef] [Scilit]
  27. Tampa, M.; Georgescu, S.R.; Mitran, C.I.; Mitran, M.I.; Matei, C.; Scheau, C.; Constantin, C.; Neagu, M. Recent Advances in Signaling Pathways Comprehension as Carcinogenesis Triggers in Basal Cell Carcinoma. J. Clin. Med. 2020, 9, 3010. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. El-Kholy, M.A.; Abu-Seadah, S.S.; Hasan, A.; Elhussiny, M.E.A.; Abdelwahed, M.S.; Hanbazazh, M.; Samman, A.; Alrashdi, S.A.; Rashed, Z.F.; Ashmawy, D.; et al. The Role of Epithelial Cell Adhesion Molecule Cancer Stem Cell Marker in Evaluation of Hepatocellular Carcinoma. Medicina 2024, 60, 915. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Charkhchi, P.; Cybulski, C.; Gronwald, J.; Wong, F.O.; Narod, S.A.; Akbari, M.R. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers 2020, 12, 3730. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Poletto, G.; Cecchin, D.; Sperti, S.; Filippi, L.; Realdon, N.; Evangelista, L. Head-to-Head Comparison between Peptide-Based Radiopharmaceutical for PET and SPECT in the Evaluation of Neuroendocrine Tumors: A Systematic Review. Curr. Issues Mol. Biol. 2022, 44, 5516–5530. [Google Scholar] [CrossRef] [Scilit]
  31. Shin, H.; Kim, H.; Kim, G.; Kim, Y.; Kim, B. Enhanced Bioactivity of Fermented Aralia cordata Extract for Glucose and Immune Modulation. Curr. Issues Mol. Biol. 2025, 47, 294. [Google Scholar] [CrossRef] [Scilit]
  32. Periferakis, A.; Tsigas, G.; Periferakis, A.-T.; Tone, C.M.; Hemes, D.A.; Periferakis, K.; Troumpata, L.; Badarau, I.A.; Scheau, C.; Caruntu, A.; et al. Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias. Curr. Issues Mol. Biol. 2024, 46, 9721–9759. [Google Scholar] [CrossRef] [Scilit]
  33. Periferakis, A.; Tsigas, G.; Periferakis, A.T.; Badarau, I.A.; Scheau, A.E.; Tampa, M.; Georgescu, S.R.; Didilescu, A.C.; Scheau, C.; Caruntu, C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal. Cell. Pathol. 2021, 2021, 1840069. [Google Scholar] [CrossRef] [Scilit]
  34. Petrov, M.; Makarova, N.; Monemian, A.; Pham, J.; Lekka, M.; Sokolov, I. Detection of Human Bladder Epithelial Cancerous Cells with Atomic Force Microscopy and Machine Learning. Cells 2025, 14, 14. [Google Scholar] [CrossRef] [Scilit]
  35. Devnath, L.; Arora, P.; Carraro, A.; Korbelik, J.; Keyes, M.; Wang, G.; Guillaud, M.; MacAulay, C. Recognizing Epithelial Cells in Prostatic Glands Using Deep Learning. Cells 2025, 14, 737. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Olawade, D.B.; Oisakede, E.O.; Egbon, E.; Ovsepian, S.V.; Boussios, S. Immune Organoids: A Review of Their Applications in Cancer and Autoimmune Disease Immunotherapy. Curr. Issues Mol. Biol. 2025, 47, 653. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Timofticiuc, I.-A.; Caruntu, A.; Dragosloveanu, C.D.M.; Scheau, A.-E.; Badarau, I.A.; Periferakis, A.; Dragosloveanu, S.; Didilescu, A.C.; Caruntu, C.; Scheau, C. Head and Neck 3D Bioprinting—A Review on Recent Advancements in Soft Tissue 3D Bioprinting and Medical Applications. J. Funct. Biomater. 2025, 16, 240. [Google Scholar] [CrossRef] [Scilit]
  38. Panraksa, P.; Jantrawut, P.; Teoh, X.Y.; Sengtakdaed, K.; Pornngam, P.; Chaiwarit, T.; Chantadee, T.; Jantanasakulwong, K.; Udomsom, S.; Zhang, B. Formulation and Structural Optimisation of PVA-Fibre Biopolymer Composites for 3D Printing in Drug Delivery Applications. Polymers 2025, 17, 2502. [Google Scholar] [CrossRef] [Scilit]
  39. Shankavaram, V.; Shah, D.; Alashqar, A.; Sweeney, J.; Arnouk, H. Cornulin as a Key Diagnostic and Prognostic Biomarker in Cancers of the Squamous Epithelium. Genes 2024, 15, 1122. [Google Scholar] [CrossRef] [Scilit]
  40. Mathur, K.; Khaliq, A.; Park, S.; Chu, N.; Burra, V.M.; Kanukolanu, N.; Costello, E.; Dakshanamurthy, S. Uncovering the Tumorigenic Blueprint of PFOS and PFOA Through Multi-Organ Transcriptomic Analysis of Biomarkers, Mechanisms, and Therapeutic Targets. Curr. Issues Mol. Biol. 2025, 47, 763. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  41. Alghamdi, H.A.; Alghamdi, S.S.; Al-Zahrani, M.H.; Trivilegio, T.; Bahattab, S.; AlRoshody, R.; Alhaidan, Y.; Alghamdi, R.A.; Matou-Nasri, S. Reticuline and Coclaurine Exhibit Vitamin D Receptor-Dependent Anticancer and Pro-Apoptotic Activities in the Colorectal Cancer Cell Line HCT116. Curr. Issues Mol. Biol. 2025, 47, 810. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Gallegos, C.A.; Lee, B.P.; Kasten, B.B.; Rogers, J.M.; Cardenas, C.E.; Warram, J.M.; Markert, J.M.; Sorace, A.G. Challenges and Opportunities in High-Grade Glioma Management and Imaging-Based Response Monitoring During Novel Immunotherapies. Cancers 2025, 17, 3176. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Timofticiuc, I.A.; Dragosloveanu, S.; Caruntu, A.; Scheau, A.E.; Badarau, I.A.; Garofil, N.D.; Didilescu, A.C.; Caruntu, C.; Scheau, C. 3D Bioprinting in Limb Salvage Surgery. J. Funct. Biomater. 2024, 15, 383. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Hsieh, H.-L.; Yu, M.-C.; Chang, Y.-C.; Wu, Y.-H.; Huang, K.-H.; Tsai, M.-M. Lonicera japonica Thunb. Ethanol Extract Exerts a Protective Effect on Normal Human Gastric Epithelial Cells by Modulating the Activity of Tumor-Necrosis-Factor-α-Induced Inflammatory Cyclooxygenase 2/Prostaglandin E2 and Matrix Metalloproteinase 9. Curr. Issues Mol. Biol. 2024, 46, 7303–7323. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Potential Use of VYN202, a Novel Small Molecular Bromodomain and Extra-Terminal Inhibitor, in Mitigating Secondhand Smoke (SHS)-Induced Pulmonary Inflammation
Previous
Mechanistic Insights into Antioxidant Interventions Targeting Obesity-Induced Oxidative Stress in the Pathogenesis and Complications of Type 2 Diabetes Mellitus
Next